Tue, May 13, 12:12 PM (39 days ago)
**BioForce Nanosciences Holdings, Inc. (BFNH) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 for Q1 2025, consistent with Q1 2024. - **Net Loss:** $934,650 for Q1 2025, significantly higher than $130,813 in Q1 2024, due to a $801,193 loss on liability settlement. - **Gross Margin:** 0% for both periods, as no sales were made. - **Operating Expenses:** $133,457 for Q1 2025, slightly higher than $130,813 in Q1 2024. - **Cash Flow:** Net cash used in operations was $15,215 for Q1 2025, compared to $17,581 in Q1 2024. - **Liquidity:** Cash on hand was $13,799 as of March 31, 2025, up from $862 at the end of 2024. - **Liabilities:** Total liabilities were $275,041, with a significant portion due to related parties. - **Stockholders' Deficit:** $261,242 as of March 31, 2025, indicating a challenging financial position. **Trends & Uncertainties:** - **Revenue Generation:** BFNH has not generated revenue from its core business, relying on related party funding. - **Operational Challenges:** The company faces significant operational and financial challenges, including a going concern uncertainty. - **Market Strategy:** BFNH is focusing on expanding its marketing efforts and establishing vendor relationships to drive sales. **Future Operations Impact:** - **Funding:** BFNH will need to secure additional funding to continue operations and implement its business plan. - **Business Model:** The company is shifting its focus to the nutritional supplements market, aiming to become a leading provider. - **Risk Factors:** BFNH faces risks related to its financial condition, market acceptance of its products, and regulatory compliance. **Ticker:** BFNH **Note:** Amounts are in thousands, 000s. The company's financial statements are unaudited and subject to change. The information provided is based on the Q1 2025 10-Q filing.